Phase 2 study of the treatment of antiretroviral treatment-experienced subjects comparing ritonavir-boosted GS-9137 [elvitegravir, JTK 303; Gilead Sciences] (GS-9137/4) vs. a comparator ritonavir-boosted protease inhibitor (CPI/r) in combination with background ART [antiretroviral therapy]

Trial Profile

Phase 2 study of the treatment of antiretroviral treatment-experienced subjects comparing ritonavir-boosted GS-9137 [elvitegravir, JTK 303; Gilead Sciences] (GS-9137/4) vs. a comparator ritonavir-boosted protease inhibitor (CPI/r) in combination with background ART [antiretroviral therapy]

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2010

At a glance

  • Drugs Elvitegravir; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2010 Results were published in the Journal of Infectious Diseases.
    • 28 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 20 Sep 2007 Interim results reported at ICAAC 2007
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top